The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.37

Today's change-0.02 -0.84%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.37

Today's change-0.02 -0.84%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc down (U.S.)$0.02

PDL BioPharma Inc closed lower Friday, dropping (U.S.)$0.02 or 0.84% to (U.S.)$2.37. Shares have lost 2.87% over the last five days, but have gained 11.79% over the last year to date. This security has underperformed the S&P 500 by 46.67% during the last year.

Key company metrics

  • Open(U.S.) $2.41
  • Previous close(U.S.) $2.39
  • High(U.S.) $2.41
  • Low(U.S.) $2.36
  • Bid / Ask(U.S.) $2.16 / (U.S.) $2.59
  • YTD % change+11.79%
  • Volume1,242,252
  • Average volume (10-day)1,082,226
  • Average volume (1-month)1,359,786
  • Average volume (3-month)1,692,620
  • 52-week range(U.S.) $1.93 to (U.S.) $3.77
  • Beta0.67
  • Trailing P/E26.04×
  • P/E 1 year forward9.23×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.09
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.02%

Based on its net profit margin of 8.02%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue45665421
Total other revenue--------
Total revenue45665421
Gross profit4362----
Total cost of revenue34----
Total operating expense27772110
Selling / general / administrative1513107
Research & development222--
Depreciation / amortization666--
Interest expense (income), net operating--------
Unusual expense (income)--5713
Other operating expenses, total1-62--
Operating income19-103311
Interest income (expense), net non-operating-5-5-5-4
Gain (loss) on sale of assets--------
Other--------
Income before tax14-15287
Income after tax7-10144
Income tax, total7-4143
Net income7-10144
Total adjustments to net income--------
Net income before extra. items7-10144
Minority interest000--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7-10144
Inc. avail. to common incl. extra. items7-10144
Diluted net income7-10144
Dilution adjustment--------
Diluted weighted average shares164164164164
Diluted EPS excluding extraordinary itemsvalue per share0.04-0.060.080.03
Dividends per sharevalue per share0.00--0.000.05
Diluted normalized EPSvalue per share0.040.160.090.04